Home  |  Site Map  |  Contact Us  |  
Search

 

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing Horizant® (gabapentin enacarbil) Extended-Release Tablets, its first approved product in the United States, and developing a novel fumaric acid ester product candidate, XP23829, as a potential treatment for relapsing-remitting multiple sclerosis and/or psoriasis. Regnite is being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease.

For more information, please click here


For more information, please click here

Thu, 24 Apr 2014
XenoPort to Present New Data for Novel Fumarate Analog XP23829 and HORIZANT at the 66th Annual Meeting of the American Academy of Neurology

Tue, 22 Apr 2014
XenoPort Files Definitive Proxy Materials and Mails Letter to Stockholders

 

2014 Cowen and Company 34th Annual Health Care Conference
Wednesday, March 5, 2014 5:00 PM ET

RBC Capital Markets' Global Healthcare Conference
February 25, 2014 2:35 PM ET

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis.

Explore the XenoPort Pipeline >